Furthermore, it would be interesting to investigate whether IDH1/2 inhibitors (which can also induce a differentiation syndrome [45,46,47]) are preferentially active or more likely to cause differentiation syndrome in (IDH1/2-mutated) “APL-like” NPM1m AML rather than in NPM1-wild-type AML with IDH1/2 mutations. This evidence concerns the gene NPM1 and acute myeloid leukemia.